Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes

Housman, 1998, Why pharmacogenomics? Why now?, Nature Biotechnol, 16, 2, 10.1038/5134 Ginsburg, 2001, Personalized medicine: revolutionizing drug discovery and patient care, Trends Biotechnol, 19, 491, 10.1016/S0167-7799(01)01814-5 Vizirianakis, 2004, Challenges in current drug delivery from the potential application of pharmacogenomics and personalized medicine in clinical practice, Curr Drug Deliv, 1, 73, 10.2174/1567201043480009 Sullenger, 2002, Emerging clinical applications of RNA, Nature, 418, 252, 10.1038/418252a Chien, 2002, Optimisation of treatment by applying programmable rate-controlled drug delivery technology, Clin Pharmacokinet, 41, 1267, 10.2165/00003088-200241150-00003 Braeckmans, 2002, Encoding microcarriers: present and future technologies, Nat Rev Drug Disc, 1, 447, 10.1038/nrd817 Collins, 2003, A vision for the future of genomics research, Nature, 422, 835, 10.1038/nature01626 Vizirianakis, 2007, From defining bioinformatics and pharmacogenomics to developing information-based medicine and pharmacotyping in healthcare, 201 Huttenhower, 2010, A quick guide to large-scale genomic data mining, PLoS Comput Biol, 6, e1000779, 10.1371/journal.pcbi.1000779 Roses, 2000, Pharmacogenetics and the practice of medicine, Nature, 405, 857, 10.1038/35015728 Evans, 1999, Pharmacogenomics: translating functional genomics into rational therapeutics, Science, 286, 487, 10.1126/science.286.5439.487 McLeod, 2001, Pharmacogenomics: unlocking the human genome for better drug therapy, Annu Rev Pharmacol Toxicol, 41, 101, 10.1146/annurev.pharmtox.41.1.101 Vizirianakis, 2007, The transformation of pharmacogenetics into pharmacogenomics reinforces personalized medicine towards pharmacotyping for improved patient care, 1 Vizirianakis, 2005, Improving pharmacotherapy outcomes by pharmacogenomics: From expectation to reality?, Pharmacogenomics, 6, 701, 10.2217/14622416.6.7.701 Manasco, 2002, Pharmacogenetics and the genetic basis of ADRs, 516 Weinshilboum, 2003, Inheritance and drug response, N Engl J Med, 348, 529, 10.1056/NEJMra020021 Meyer, 2000, Pharmacogenetics and adverse drug reactions, Lancet, 356, 1667, 10.1016/S0140-6736(00)03167-6 Silber, 2003, Pharmacogenomics, biomarkers, and the promise of personalized medicine, 11 Spear, 2001, Clinical application of pharmacogenetics, Trends Mol Med, 7, 201, 10.1016/S1471-4914(01)01986-4 Lazarou, 1998, Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies, JAMA, 279, 1200, 10.1001/jama.279.15.1200 2000, 1 Flockhart, 2002, Implications of cytochrome P450 interactions when prescribing medication for hypertension, Arch Intern Med, 162, 405, 10.1001/archinte.162.4.405 Ingelman-Sundberg, 2004, Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future, Trends Pharmacol Sci, 25, 193, 10.1016/j.tips.2004.02.007 Ebbesen, 2001, Drug-related deaths in a department of internal medicine, Arch Intern Med, 61, 2317, 10.1001/archinte.161.19.2317 Evans, 2003, Drug disposition, drug targets, and side effects, N Engl J Med, 348, 538, 10.1056/NEJMra020526 Robertson, 2000, DNA methylation in health and disease, Nat Rev Genet, 1, 11, 10.1038/35049533 Johnstone, 2002, Histone-deacetylase inhibitors: novel drugs for the treatment of cancer, Nature Rev Drug Disc, 1, 287, 10.1038/nrd772 Ingelman-Sundberg, 2010, The past, present and future of pharmacoepigenomics, Pharmacogenomics, 11, 625, 10.2217/pgs.10.59 Goldstein, 2003, Pharmacogenetics in the laboratory and the clinic, N Engl J Med, 348, 553, 10.1056/NEJMe020173 International Transporter Consortium, 2010, Membrane transporters in drug development, Nat Rev Drug Discov, 9, 215, 10.1038/nrd3028 Phillips, 2001, Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review, JAMA, 286, 2270, 10.1001/jama.286.18.2270 Vizirianakis, 2010, Clinical and pharmacogenomic assessment of herb-drug interactions to improve drug delivery and pharmacovigilance, 199 Vizirianakis, 2007, Clinical translation of genotyping and haplotyping data: implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping, Clin Pharmacokinet, 46, 807, 10.2165/00003088-200746100-00001 Vizirianakis, 2010, Toward the development of innovative bi-functional agents to induce differentiation and promote apoptosis in leukemia: clinical candidates and perspectives, J Med Chem, 53, 6779, 10.1021/jm100189a Ahn, 2010, Functional mapping of drug response with pharmacodynamic-pharmacokinetic principles, Trends Pharmacol Sci, 31, 306, 10.1016/j.tips.2010.04.004 Caruthers, 2007, Nanotechnological applications in medicine, Curr Opin Biotechnol, 18, 26, 10.1016/j.copbio.2007.01.006 Davis, 2008, Nanoparticle therapeutics: an emerging treatment modality for cancer, Nat Rev Drug Discov, 7, 771, 10.1038/nrd2614 Debbage, 2009, Targeted drugs and nanomedicine: present and future, Curr Pharm Des, 5, 153, 10.2174/138161209787002870 Lammers, 2010, Nanotheranostics and image-guided drug delivery: current concepts and future directions, Mol Pharm, 10.1021/mp100228v Marchant, 2009, Small is beautiful: what can nanotechnology do for personalized medicine?, Curr Pharmacogenomics Personalized Med, 7, 231, 10.2174/187569209790112346 Jain, 2010, Innovative diagnostic technologies and their significance for personalized medicine, Mol Diagn Ther, 14, 141, 10.1007/BF03256366 van den Akker-van Marle, 2006, Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe, Pharmacogenomics, 7, 783, 10.2217/14622416.7.5.783 Gurwitz, 2009, Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain, Eur J Hum Genet, 17, 991, 10.1038/ejhg.2009.10 Fleeman, 2010, The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation, Health Technol Assess, 14, 1, 10.3310/hta14030 McKinnon, 2007, A critical analysis of barriers to the clinical implementation of pharmacogenomics, Ther Clin Risk Manag, 3, 751 Wu, 2009, Implementation of pharmacogenomics into the clinical practice of therapeutics: issues for the clinician and the laboratorian, Personalized Med, 6, 315, 10.2217/pme.09.1 Flowers, 2004, The role of cost-effectiveness analysis in the era of pharmacogenomics, Pharmacoeconomics, 22, 481, 10.2165/00019053-200422080-00001 Payne, 2010, Cost-effectiveness analysis in pharmacogenomics, Pharmacogenomics, 11, 643, 10.2217/pgs.10.45 Wong, 2010, Cost effectiveness of pharmacogenomics: a critical and systematic review, Pharmacoeconomics, 28, 1001, 10.2165/11537410-000000000-00000 Halapi, 2002, Advances in the development of genetic markers for the diagnosis of disease and drug response, Expert Rev Mol Diagn, 2, 411, 10.1586/14737159.2.5.411 Johnson, 2002, Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity, Trends Mol Med, 8, 300, 10.1016/S1471-4914(02)02354-7 Dequeker, 2001, Quality control in molecular genetic testing, Nat Rev Genet, 2, 717, 10.1038/35088588 Lewin, 2004, Molecular biomarkers in drug development, Drug Discov Today, 9, 976, 10.1016/S1359-6446(04)03272-6 Hall, 2003, Molecular diagnostics: a healthcare perspective, Expert Rev Mol Diagn, 3, 13, 10.1586/14737159.3.1.13 Sangkuhl, 2008, PharmGKB: understanding the effects of individual genetic variants, Drug Metab Rev, 40, 539, 10.1080/03602530802413338 Weinshilboum, 2004, Pharmacogenomics: bench to bedside, Nat Rev Drug Discov, 3, 739, 10.1038/nrd1497 Vizirianakis, 2002, Pharmaceutical education in the wake of genomic technologies for drug development and personalized medicine, Eur J Pharm Sci, 15, 243, 10.1016/S0928-0987(02)00013-1 Gurwitz, 2003, Education: teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine, Trends Pharmacol Sci, 24, 122, 10.1016/S0165-6147(03)00024-5 Henry, 2008, Drug interactions and pharmacogenomics in the treatment of breast cancer and depression, Am J Psychiatry, 165, 1251, 10.1176/appi.ajp.2008.08040482 Hoskins, 2009, CYP2D6 and tamoxifen: DNA matters in breast cancer, Nat Rev Cancer, 9, 576, 10.1038/nrc2683 Kelly, 2010, Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study, Br Med J, 340, c693, 10.1136/bmj.c693 Sideras, 2010, Co-prescription of tamoxifen and medications that inhibit CYP2D6, J Clin Oncol, 28, 2768, 10.1200/JCO.2009.23.8931 Lash, 2010, Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy, J Clin Oncol, 28, 1273, 10.1200/JCO.2009.26.7906 Keller, 2010, Coriell Personalized Medicine Collaborative: a prospective study of the utility of personalized medicine, Personalized Med, 7, 310, 10.2217/pme.10.13